Home » Canada Pharmaceuticals Market

Canada Pharmaceuticals Market By Pharmaceutical Product Categories (Prescription Pharmaceuticals, Over-the-counter (OTC) Pharmaceuticals, Generic Pharmaceuticals, Biopharmaceuticals and Biologics, Specialty Pharmaceuticals, Vaccines) By Therapeutic Areas (Cardiovascular Pharmaceuticals, Oncology Pharmaceuticals, Central Nervous System (CNS) Pharmaceuticals, Infectious Disease Pharmaceuticals and Others) By Regulatory Compliance and Approval (Health Canada, Patent and Generic Drugs, Biosimilars, Clinical Trials) By Research and Development (R&D) (Innovative Drug Discovery, Clinical Development, Regulatory Affairs and Approvals) By Pharmaceutical Services and Solutions (Pharmaceutical Services Providers, Pharmaceutical Packaging Solutions, Pharmaceutical Consulting and Contract Research) By Pharmaceutical Manufacturing (Domestic Manufacturing, Imported Pharmaceuticals)- Growth, Future Prospects & Competitive Analysis, 2022 – 2030

Price: $1999

Published: | Report ID: 30503 | Report Format : PDF

Market Insights

  • The Canadian demand for pharmaceuticals was valued at USD 31154.5 million in 2022 and is expected to reach USD 46735.47 million in 2030, growing at a CAGR of 5.20% between 2023 and 2030.
  • Over-the-counter (OTC) pharmaceuticals are the leading segment by pharmaceutical product categories. On the other hand, prescription pharmaceuticals are expected to grow at a strong CAGR.
  • The leading therapeutic area segment is cardiovascular pharmaceuticals.
  • The CAGR for hospital pharmacies segment is expected to be the highest during the projection period.
  • During the forecast time frame, the Health Canada category will likely have the highest CAGR.
  • The innovative drug discovery segment is estimated to have the greatest CAGR during the forecast period.
  • The pharmaceutical services providers segment will likely have the highest CAGR during the prediction period.
  • The domestic manufacturing segment’s CAGR will be the top during the projected period.
  • The main drivers of the Canadian pharmaceutical market are the growing adoption of value-based care, rising demand for biosimilars, increasing consumer demand for self-medication, and the rise of specialty pharmaceuticals.
  • With the increasing use of telemedicine, new developments in digital health, and the evolving role of chemists, the Canadian pharmaceutical market presents many prospects for expansion.

Canada Pharmaceuticals Market

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Executive Summary

Market Definition

The Canadian pharmaceutical market refers to the economic sector that encompasses the production, distribution, and retailing of pharmaceutical products inside Canada. This market includes vaccinations, over-the-counter and prescription medications, and other healthcare goods. Health Canada regulates this vital market, impacted by healthcare policies, regulatory frameworks, and shifting consumer needs.

Market Overview

The market for Canadian pharmaceuticals has been expanding steadily in recent years. Between 2023 and 2030, it is anticipated to rise at a CAGR of 5.20%. The market was estimated to be worth USD 31154.5 million in 2022, and it is anticipated to be worth USD 46735.47 million in 2030.

One of the primary factors driving the market’s growth is the rising incidence of topical illnesses in Canada. In October 2021, for example, the Canadian Dermatology Association published an article stating that approximately 17% of Canadians had, at some point in their life, dealt with atopic dermatitis (AD). Eczema, most commonly known as atopic dermatitis (AD), is characterized by itchy, inflammatory skin. OTC medicine purchases are common for AD patients, contributing to the expansion of the market.

Furthermore, Canada has a large pharmaceutical market for treating atopic dermatitis. For instance, emollients, moisturizers, corticosteroids, antibiotics, and antihistamines. Numerous products are being introduced to treat this illness, though. Health Canada approved AbbVie’s RINVOQ medication for atopic dermatitis in October 2021. It can be used to treat people with resistant moderate to severe AD and adolescents 12 years of age and older when systemic therapies are not effective or wise.

It is also observed that melanoma and other skin conditions significantly drive the market’s growth. The early signs of melanoma include skin darkening, changes in the color of moles, or irregularly shaped moles. Until a cancer diagnosis is made, individuals treat the early symptoms with over-the-counter medication. Data released in June 2022 by the Canadian Dermatology Association shows that melanoma prevalence is rising annually in Canada, driving up demand for over-the-counter topical medications.

Segmentation by Pharmaceutical Product Categories

  • Over-the-counter (OTC) pharmaceuticals are the market leader in pharmaceutical product categories. OTC pain relievers, such as acetaminophen, ibuprofen, and aspirin, are widely used for managing mild to moderate pain, including headaches, muscle aches, and joint pain. OTC medications like acetaminophen and ibuprofen are commonly used to reduce fever associated with various illnesses, such as the common cold or flu.
  • The prescription pharmaceuticals category will exhibit a sizable CAGR during the projected period. Prescribed to treat bacterial infections, antibiotics are essential for conditions such as respiratory infections, urinary tract infections, and skin infections.
  • Other pharmaceutical product categories, such as generic pharmaceuticals, biopharmaceuticals and biologics, specialty pharmaceuticals, and vaccines, also contribute to the demand for Canadian pharmaceuticals.

Segmentation by Therapeutic Areas

  • The main therapeutic area category is cardiovascular pharmaceuticals. Medications in this category include beta-blockers, diuretics, calcium channel blockers, angiotensin II receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors, which treat and regulate high blood pressure.
  • The oncology pharmaceuticals category will likely register a significant CAGR during forecasting. This is due to the use of high-dose radiation to kill or damage cancer cells. It is often used as a localized treatment or combined with other cancer therapies.
  • Other therapeutic areas, such as central nervous system (CNS) pharmaceuticals, infectious disease pharmaceuticals, respiratory pharmaceuticals, gastrointestinal pharmaceuticals, immunology and rheumatology pharmaceuticals, endocrinology pharmaceuticals, dermatology pharmaceuticals, ophthalmology pharmaceuticals, hematology pharmaceuticals, urology pharmaceuticals, also contribute to the demand for Canada pharmaceuticals.

Segmentation by Pharmaceutical Distribution Channels

  • The hospital pharmacies category is anticipated to experience the highest CAGR during the projection period. Hospital pharmacies are responsible for procuring, storing, dispensing, and managing medications within the hospital setting. They source pharmaceutical products from wholesalers and ensure patients receive the right medications at the right time.
  • Other pharmaceutical distribution channels, such as pharmaceutical manufacturers, pharmaceutical wholesalers and distributors, community pharmacies, and online pharmacies, also contribute to the demand for Canadian pharmaceuticals.

Segmentation by Regulatory Compliance and Approval

  • During the projection period, Health Canada will likely have the highest CAGR. The Therapeutic Products Directorate (TPD), part of Health Canada, regulates pharmaceutical drugs and medical devices in Canada. It assesses the safety, efficacy, and quality of these products before they are allowed to be marketed.
  • Other regulatory compliance and approval, such as patent and generic drugs, biosimilars, and clinical trials, also contribute to Canada’s pharmaceutical demand.

Segmentation by Research and Development (R&D)

  • Innovative drug discovery will have the highest CAGR during the prediction period. Drug discovery typically begins with identifying a specific molecular target associated with a disease or condition. Researchers then validate that the target is relevant to the disease and could be modulated for therapeutic benefit.
  • Other research and development (R&D), such as clinical development, regulatory affairs, and approvals, also contribute to Canada’s pharmaceutical demand.

Segmentation by Pharmaceutical Services and Solutions

  • The pharmaceutical service providers category is anticipated to have the greatest CAGR throughout the forecast duration. Contract development and manufacturing organizations (CDMOs) provide drug development and manufacturing services. This includes drug formulation, process development, scale-up, and commercial manufacturing of pharmaceutical products.
  • Other pharmaceutical services and solutions, such as pharmaceutical packaging solutions, pharmaceutical consulting, and contract research, also contribute to the demand for Canadian pharmaceuticals.

Segmentation by Pharmaceutical Manufacturing

  • The highest CAGR is anticipated for domestic manufacturing throughout estimation. Considerations of public health preparedness underscore the importance of domestic pharmaceutical manufacturing. The ability to produce essential medications, including vaccines and treatments, domestically contributes to the country’s readiness to respond to public health emergencies and pandemics.
  • Other pharmaceutical manufacturing, such as imported pharmaceuticals, also contribute to the demand for Canadian pharmaceuticals.

The Diabetes in Canada 2021 report estimates that more than 11 million Canadians suffer from diabetes or prediabetes. Globally, diabetes is expected to impact 4,891,000 individuals by 2030. The total number of individuals with prediabetes and diabetes is expected to reach 13,559,000 by 2030. As the disease’s prevalence rises, so will the need for pharmaceutical therapy. More treatments are needed to address the rising number of diabetes cases.

The government’s countrywide focus on the pharmaceutical industry also contributes to the market’s growth. For example, in August 2021, the Canadian government announced increased funding for diabetes research. The government intended to allocate about USD 15 million to fund diabetes research. These investments should play a significant role in the Canadian market’s growth.

Key Highlights of the Report

The Canadian pharmaceutical market is segmented by pharmaceutical product categories, therapeutic areas, pharmaceutical distribution channels, regulatory compliance and approval, research and development (R&D), pharmaceutical services and solutions, and pharmaceutical manufacturing. Over-the-counter (OTC) Pharmaceuticals are the market spearhead regarding the pharmaceutical product categories. Cardiovascular pharmaceuticals are the top therapeutic areas segment. The hospital pharmacies category is expected to grow at the highest CAGR during the forecast period. The Health Canada category is anticipated to experience the highest CAGR during the forecast period.

The pharmaceutical market in Canada is growing due to significant advancements in medical technology. Technological advancements, including genomics and molecular diagnostics, enable a deeper understanding of individual patient profiles. This facilitates the development of personalized and targeted pharmaceutical interventions. High-throughput screening, computational biology, and bioinformatics contribute to the acceleration of drug discovery processes. Advanced technologies allow for more efficient identification and validation of potential drug candidates. Advances in biotechnology, including recombinant DNA technology and protein engineering, drive the development of biopharmaceuticals such as monoclonal antibodies and gene therapies, expanding treatment options.

AI and machine learning algorithms analyze vast datasets to identify patterns and trends. In pharmaceuticals, these technologies assist in drug design, patient stratification, and clinical trial optimization. 3D printing technology allows for the precise manufacturing of pharmaceuticals, enabling personalized dosages and formulations. This can enhance drug delivery and improve patient compliance. Nanotechnology is applied in drug delivery systems, improving pharmaceuticals’ bioavailability and targeted delivery. This can enhance the efficacy of treatments while minimizing side effects.

Which Key Factors Are Driving The Canadian Pharmaceutical Market?

The rising prevalence of chronic diseases, the growing elderly population, the advancements in medical technology, and the increasing demand for personalized medicine drive the pharmaceutical market’s expansion in Canada.

What Are The Key Challenges In The Canada Market For Pharmaceuticals?

Several challenges, including the stringent regulatory environment, drug pricing and reimbursement pressures, patent expirations and generic competition, and rising research and development costs, impede the growth of the Canadian pharmaceutical market.

What Market Opportunities Exist For Canada Pharmaceuticals?

There is increasing demand for biopharmaceuticals and biotechnology, rising digital health integration, growing specialized therapeutics, and generic drugs and biosimilars. These factors create significant opportunities for the Canadian pharmaceutical market.

Market Drivers

Several factors influence the market for Canada-pharmaceutical. The main factors influencing the market for Canadian pharmaceuticals are as follows:

Rising Prevalence Of Chronic Diseases

The growing incidence of chronic illnesses is one of the main factors propelling the Canadian pharmaceutical market’s growth. Canada has an aging population, with many individuals entering the older age brackets. Aging is often associated with an increased risk of chronic diseases such as cardiovascular diseases, diabetes, and neurodegenerative disorders. The overall improvement in healthcare and living conditions has led to an increase in life expectancy. However, with longer life comes an elevated risk of developing chronic conditions, driving the need for pharmaceutical interventions. Changes in lifestyle, including sedentary behavior, unhealthy dietary habits, and increased stress, contribute to the rising incidence of chronic diseases. Lifestyle-related conditions like obesity and metabolic disorders often require pharmaceutical interventions. Cardiovascular diseases, including hypertension and heart-related conditions, are among the leading causes of morbidity in Canada. The pharmaceutical industry responds with medications to manage and treat these conditions.

Market Restraints

Several challenges could prevent the expansion of the Canadian pharmaceuticals market. Among them are the following:

Drug Pricing and Reimbursement Pressures

The Canadian pharmaceutical market may be impacted by major restraints associated with drug pricing and reimbursement concerns. The reimbursement process often involves pharmacoeconomic evaluations, where the cost-effectiveness of a drug is assessed. If a drug’s cost-effectiveness is deemed inadequate, it may face challenges in obtaining favorable reimbursement. Reference pricing, where the price of a drug is compared to that of similar products, and Health Technology Assessment (HTA) processes influence reimbursement decisions. This can lead to pricing pressures and impact market access. Pharmaceutical companies often negotiate with public and private payers to secure favorable reimbursement terms. These negotiations can be complex and may impact the overall profitability of a drug.

Opportunities

The Canadian pharmaceutical market presents significant potential opportunities. The following is an example of these:

Expanding Digital Health Integration

The integration of digital health technologies is a key driver for the growth of the pharmaceutical market in Canada. Digital health solutions can enhance patient outcomes, improve healthcare delivery, and contribute to the overall efficiency of the healthcare system. Digital health technologies enable remote monitoring of patients with chronic conditions. This can lead to better medication adherence, early detection of issues, and improved management of chronic diseases. Telemedicine platforms and virtual care solutions facilitate remote consultations and healthcare services. Digital tools allow pharmaceutical companies to engage with patients and healthcare providers and offer support services. Integrating electronic health records (EHRs) and health information systems allows pharmaceutical companies to access real-time patient data, enabling personalized medicine approaches and better-informed treatment decisions.

Competitive Landscape

Canada Pharmaceuticals Market Report

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Key Players

The Canadian pharmaceutical market is very competitive, with many powerful players. Some of the leading market participants and their corresponding market shares are listed below:

  • Johnson & Johnson
  • Novartis International AG
  • Abbott Laboratories
  • Merck & Co. Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • AbbVie Inc.
  • Apotex Inc.
  • Others

These companies prioritize mergers and acquisitions, expanding their distribution network, and developing new products to remain competitive.

The leading competitors in the Canadian market are constantly looking for ways to get an advantage by releasing new items and advancements.

In October 2022, Alvotech and the Canadian pharmaceutical business JAMP Pharma Group announced they are expanding their exclusive partnership to market biosimilars (AVT16 & AVT33) that Alvotech has developed and produced.

In April 2022, the Canadian-owned pharmaceutical business AMP Pharma Group announced the release of SIMLANDI, a high-concentration, low-volume, citrate-free biosimilar to Humira (adalimumab) developed by Alvotech.

Summary of Key Findings

  • The Canadian pharmaceutical market continues to grow due to the rising incidence of chronic diseases.
  • The market is segmented by pharmaceutical product categories, therapeutic areas, pharmaceutical distribution channels, regulatory compliance and approval, research and development (R&D), pharmaceutical services and solutions, and pharmaceutical manufacturing.
  • Over-the-counter (OTC) pharmaceuticals are the market’s most preferred pharmaceutical product categories.
  • Cardiovascular pharmaceuticals are the most common in terms of therapeutic areas.
  • Regarding CAGR, hospital pharmacies are expected to grow fastest during the forecast period.
  • The categories for Health Canada will likely see the highest CAGR during the anticipated time frame.
  • The Canada pharmaceutical market is highly competitive with key players including Johnson & Johnson, Novartis International AG, Abbott Laboratories, Merck & Co. Inc., Pfizer Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Eli Lilly and Company, AbbVie Inc., Apotex Inc., and others.

Future Outlook

  • Optimistic viewpoint for the pharmaceutical industry with noteworthy growth potential in Canada.
  • The increasing advancements in medical technology are one of the main elements driving the expansion of the pharmaceutical market in Canada.
  • Canada Pharmaceutical’s drug pricing and compensation pressures might significantly challenge the market’s expansion during the projected period.
  • Foremost companies must concentrate on product innovation, expanding their market reach, and maintaining competitive pricing to stay ahead.

Segmentation

  • By Pharmaceutical Product Categories
    • Prescription Pharmaceuticals
    • Over-the-counter (OTC) Pharmaceuticals
    • Generic Pharmaceuticals
    • Biopharmaceuticals and Biologics
    • Specialty Pharmaceuticals
    • Vaccines
  • By Therapeutic Areas
    • Cardiovascular Pharmaceuticals
    • Oncology Pharmaceuticals
    • Central Nervous System (CNS) Pharmaceuticals
    • Infectious Disease Pharmaceuticals
    • Respiratory Pharmaceuticals
    • Gastrointestinal Pharmaceuticals
    • Immunology and Rheumatology Pharmaceuticals
    • Endocrinology Pharmaceuticals
    • Dermatology Pharmaceuticals
    • Ophthalmology Pharmaceuticals
    • Hematology Pharmaceuticals
    • Urology Pharmaceuticals
  • Pharmaceutical Distribution Channels
    • Pharmaceutical Manufacturers
    • Pharmaceutical Wholesalers and Distributors
    • Community Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
  • By Regulatory Compliance and Approval
    • Health Canada
    • Patent and Generic Drugs
    • Biosimilars
    • Clinical Trials
  • By Research and Development (R&D)
    • Innovative Drug Discovery
    • Clinical Development
    • Regulatory Affairs and Approvals
  • By Pharmaceutical Services and Solutions
    • Pharmaceutical Services Providers
    • Pharmaceutical Packaging Solutions
    • Pharmaceutical Consulting and Contract Research
  • By Pharmaceutical Manufacturing
    • Domestic Manufacturing
    • Imported Pharmaceuticals

Table of Content
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Introduction
2. Executive Summary
2.1. Market Snapshot: Canada Pharmaceutical Market
2.1.1. Canada Pharmaceutical Market, By Pharmaceutical Product Categories
2.1.2. Canada Pharmaceutical Market, By Therapeutic Areas
2.1.3. Canada Pharmaceutical Market, By Pharmaceutical Distribution Channels
2.1.4. Canada Pharmaceutical Market, By Regulatory Compliance and Approval
2.1.5. Canada Pharmaceutical Market, By Research and Development (R&D)
2.1.6. Canada Pharmaceutical Market, By Pharmaceutical Services and Solutions
2.1.7. Canada Pharmaceutical Market, By Pharmaceutical Manufacturing
2.2. Insights from Primary Respondents
3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Canada Pharmaceutical Market Value, 2017-2030, (US$ Mn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Pharmaceutical Market Drivers
3.2.2. Pharmaceutical Market Restraints
3.2.3. Pharmaceutical Market Opportunities
3.2.4. Major Pharmaceutical Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Pharmaceutical Product Categories
3.5.2. Therapeutic Areas
3.5.3. Pharmaceutical Distribution Channels
3.5.4. Regulatory Compliance and Approval
3.5.5. Research and Development (R&D)
3.5.6. Pharmaceutical Services and Solutions
3.5.7. Pharmaceutical Manufacturing
4. Market Competitive Landscape Analysis
4.1. Company Market Share Analysis, 2022
4.1.1. Canada Pharmaceutical Market: Company Market Share, Value 2022
4.1.2. Canada Pharmaceutical Market: Top 6 Company Market Share, Value 2022
4.1.3. Canada Pharmaceutical Market: Top 3 Company Market Share, Value 2022
4.2. Canada Pharmaceutical Market: Company Revenue Share Analysis, 2022
4.3. Company Assessment Metrics, 2022
4.3.1. Stars
4.3.2. Emerging Leaders
4.3.3. Pervasive Players
4.3.4. Participants
4.4. Startups/ SMEs Assessment Metrics, 2022
4.4.1. Progressive Companies
4.4.2. Responsive Companies
4.4.3. Dynamic Companies
4.4.4. Starting Blocks
4.5. Strategic Development
4.5.1. Acquisition and Mergers
4.5.2. New Product Launch
4.5.3. Regional Expansion
4.5.4. Partnerships
4.6. Key Player Product Matrix
4.7. Potential for New Players in the Canada Pharmaceutical Market
5. Premium Insights
5.1. STAR (Situation, Task, Action, Results) Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Bargaining Power of Buyers/Consumers
5.2.3. Bargaining Power of Suppliers
5.2.4. Threat of Substitute Types
5.2.5. Intensity of Competitive Rivalry
5.3. PESTEL Analysis
5.3.1. Political Factors
5.3.2. Economic Factors
5.3.3. Social Factors
5.3.4. Technological Factors
5.3.5. Environmental Factors
5.3.6. Legal Factors
5.4. Key Market Trends
5.4.1. Demand Side Trends
5.4.2. Supply Side Trends
5.5. Value Chain Analysis
5.6. Technology Analysis
5.6.1. Research and development in the Canada market
5.6.2. Patent Analysis
5.6.3. Emerging technologies and their potential disruption to the market
5.7. Consumer Behaviour Analysis
5.7.1. Consumer Preferences and Expectations
5.7.2. Factors Influencing Consumer Buying Decisions
5.7.3. Consumer Pain Points
5.8. Analysis and Recommendations
5.9. Adjacent Market Analysis
6. Market Positioning of Key Players, 2022
6.1. Company market share of key players, 2022
6.2. Competitive Benchmarking
6.3. Market Positioning of Key Vendors
6.4. Geographical Presence Analysis
6.5. Major Strategies Adopted by Key Players
6.5.1. Key Strategies Analysis
6.5.2. Mergers and Acquisitions
6.5.3. Partnerships
6.5.4. Product Launch
6.5.5. Geographical Expansion
6.5.6. Others
7. Impact Analysis of COVID 19 and Russia – Ukraine War on Canada Pharmaceutical Market
7.1. Ukraine-Russia War Impact
7.1.1. Uncertainty and Economic Instability
7.1.2. Supply chain disruptions
7.1.3. Regional market shifts
7.1.4. Shift in government priorities
7.2. COVID-19 Impact Analysis
7.2.1. Supply Chain Disruptions
7.2.2. Demand Fluctuations
7.2.3. Shift in Product Mix
7.2.4. Reduced Industrial Activity
7.2.5. Impact Analysis
7.2.5.1. Canada
8. Canada Pharmaceutical Market, By Pharmaceutical Product Categories
8.1. Canada Pharmaceutical Market Overview, by Pharmaceutical Product Categories
8.1.1. Canada Pharmaceutical Market Revenue Share, By Pharmaceutical Product Categories, 2022 Vs 2030 (in %)
8.2. Prescription Pharmaceuticals
8.2.1. Canada Pharmaceutical Market, By Prescription Pharmaceuticals, 2017-2030 (US$ Mn)
8.2.2. Market Dynamics for Prescription Pharmaceuticals
8.2.2.1. Drivers
8.2.2.2. Restraints
8.2.2.3. Opportunities
8.2.2.4. Trends
8.3. Over-the-Counter (OTC) Pharmaceuticals
8.3.1. Canada Pharmaceutical Market, By Over-the-Counter (OTC) Pharmaceuticals, 2017-2030 (US$ Mn)
8.3.2. Market Dynamics for Over-the-Counter (OTC) Pharmaceuticals
8.3.2.1. Drivers
8.3.2.2. Restraints
8.3.2.3. Opportunities
8.3.2.4. Trends
8.4. Generic Pharmaceuticals
8.4.1. Canada Pharmaceutical Market, By Generic Pharmaceuticals, 2017-2030 (US$ Mn)
8.4.2. Market Dynamics for Generic Pharmaceuticals
8.4.2.1. Drivers
8.4.2.2. Restraints
8.4.2.3. Opportunities
8.4.2.4. Trends
8.5. Biopharmaceuticals and Biologics
8.5.1. Canada Pharmaceutical Market, By Biopharmaceuticals and Biologics, 2017-2030 (US$ Mn)
8.5.2. Market Dynamics for Biopharmaceuticals and Biologics
8.5.2.1. Drivers
8.5.2.2. Restraints
8.5.2.3. Opportunities
8.5.2.4. Trends
8.6. Specialty Pharmaceuticals
8.6.1. Canada Pharmaceutical Market, By Specialty Pharmaceuticals, 2017-2030 (US$ Mn)
8.6.2. Market Dynamics for Specialty Pharmaceuticals
8.6.2.1. Drivers
8.6.2.2. Restraints
8.6.2.3. Opportunities
8.6.2.4. Trends
8.7. Vaccines
8.7.1. Canada Pharmaceutical Market, By Vaccines, 2017-2030 (US$ Mn)
8.7.2. Market Dynamics for Vaccines
8.7.2.1. Drivers
8.7.2.2. Restraints
8.7.2.3. Opportunities
8.7.2.4. Trends
9. Canada Pharmaceutical Market, By Therapeutic Areas
9.1. Canada Pharmaceutical Market Overview, by Therapeutic Areas
9.1.1. Canada Pharmaceutical Market Revenue Share, By Therapeutic Areas, 2022 Vs 2030 (in %)
9.2. Cardiovascular Pharmaceuticals
9.2.1. Canada Pharmaceutical Market, By Cardiovascular Pharmaceuticals, 2017-2030 (US$ Mn)
9.2.2. Market Dynamics for Cardiovascular Pharmaceuticals
9.2.2.1. Drivers
9.2.2.2. Restraints
9.2.2.3. Opportunities
9.2.2.4. Trends
9.3. Oncology Pharmaceuticals
9.3.1. Canada Pharmaceutical Market, By Oncology Pharmaceuticals, 2017-2030 (US$ Mn)
9.3.2. Market Dynamics for Oncology Pharmaceuticals
9.3.2.1. Drivers
9.3.2.2. Restraints
9.3.2.3. Opportunities
9.3.2.4. Trends
9.4. Central Nervous System (CNS) Pharmaceuticals
9.4.1. Canada Pharmaceutical Market, By Central Nervous System (CNS) Pharmaceuticals, 2017-2030 (US$ Mn)
9.4.2. Market Dynamics for Central Nervous System (CNS) Pharmaceuticals
9.4.2.1. Drivers
9.4.2.2. Restraints
9.4.2.3. Opportunities
9.4.2.4. Trends
9.5. Infectious Disease Pharmaceuticals
9.5.1. Canada Pharmaceutical Market, By Infectious Disease Pharmaceuticals, 2017-2030 (US$ Mn)
9.5.2. Market Dynamics for Infectious Disease Pharmaceuticals
9.5.2.1. Drivers
9.5.2.2. Restraints
9.5.2.3. Opportunities
9.5.2.4. Trends
9.6. Respiratory Pharmaceuticals
9.6.1. Canada Pharmaceutical Market, By Respiratory Pharmaceuticals, 2017-2030 (US$ Mn)
9.6.2. Market Dynamics for Respiratory Pharmaceuticals
9.6.2.1. Drivers
9.6.2.2. Restraints
9.6.2.3. Opportunities
9.6.2.4. Trends
9.7. Gastrointestinal Pharmaceuticals
9.7.1. Canada Pharmaceutical Market, By Gastrointestinal Pharmaceuticals, 2017-2030 (US$ Mn)
9.7.2. Market Dynamics for Gastrointestinal Pharmaceuticals
9.7.2.1. Drivers
9.7.2.2. Restraints
9.7.2.3. Opportunities
9.7.2.4. Trends
9.8. Immunology and Rheumatology Pharmaceuticals
9.8.1. Canada Pharmaceutical Market, By Immunology and Rheumatology Pharmaceuticals, 2017-2030 (US$ Mn)
9.8.2. Market Dynamics for Immunology and Rheumatology Pharmaceuticals
9.8.2.1. Drivers
9.8.2.2. Restraints
9.8.2.3. Opportunities
9.8.2.4. Trends
9.9. Endocrinology Pharmaceuticals
9.9.1. Canada Pharmaceutical Market, By Endocrinology Pharmaceuticals, 2017-2030 (US$ Mn)
9.9.2. Market Dynamics for Endocrinology Pharmaceuticals
9.9.2.1. Drivers
9.9.2.2. Restraints
9.9.2.3. Opportunities
9.9.2.4. Trends
9.10. Dermatology Pharmaceuticals
9.10.1. Canada Pharmaceutical Market, By Dermatology Pharmaceuticals, 2017-2030 (US$ Mn)
9.10.2. Market Dynamics for Dermatology Pharmaceuticals
9.10.2.1. Drivers
9.10.2.2. Restraints
9.10.2.3. Opportunities
9.10.2.4. Trends
9.11. Ophthalmology Pharmaceuticals
9.11.1. Canada Pharmaceutical Market, By Ophthalmology Pharmaceuticals, 2017-2030 (US$ Mn)
9.11.2. Market Dynamics for Ophthalmology Pharmaceuticals
9.11.2.1. Drivers
9.11.2.2. Restraints
9.11.2.3. Opportunities
9.11.2.4. Trends
9.12. Hematology Pharmaceuticals
9.12.1. Canada Pharmaceutical Market, By Hematology Pharmaceuticals, 2017-2030 (US$ Mn)
9.12.2. Market Dynamics for Hematology Pharmaceuticals
9.12.2.1. Drivers
9.12.2.2. Restraints
9.12.2.3. Opportunities
9.12.2.4. Trends
9.13. Urology Pharmaceuticals
9.13.1. Canada Pharmaceutical Market, By Urology Pharmaceuticals, 2017-2030 (US$ Mn)
9.13.2. Market Dynamics for Urology Pharmaceuticals
9.13.2.1. Drivers
9.13.2.2. Restraints
9.13.2.3. Opportunities
9.13.2.4. Trends
10. Canada Pharmaceutical Market, By Pharmaceutical Distribution Channels
10.1. Canada Pharmaceutical Market Overview, by Pharmaceutical Distribution Channels
10.1.1. Canada Pharmaceutical Market Revenue Share, By Pharmaceutical Distribution Channels, 2022 Vs 2030 (in %)
10.2. Pharmaceutical Manufacturers
10.2.1. Canada Pharmaceutical Market, By Pharmaceutical Manufacturers, 2017-2030 (US$ Mn)
10.2.2. Market Dynamics for Pharmaceutical Manufacturers
10.2.2.1. Drivers
10.2.2.2. Restraints
10.2.2.3. Opportunities
10.2.2.4. Trends
10.3. Pharmaceutical Wholesalers and Distributors
10.3.1. Canada Pharmaceutical Market, By Pharmaceutical Wholesalers and Distributors, 2017-2030 (US$ Mn)
10.3.2. Market Dynamics for Pharmaceutical Wholesalers and Distributors
10.3.2.1. Drivers
10.3.2.2. Restraints
10.3.2.3. Opportunities
10.3.2.4. Trends
10.4. Community Pharmacies
10.4.1. Canada Pharmaceutical Market, By Community Pharmacies, 2017-2030 (US$ Mn)
10.4.2. Market Dynamics for Community Pharmacies
10.4.2.1. Drivers
10.4.2.2. Restraints
10.4.2.3. Opportunities
10.4.2.4. Trends
10.5. Hospital Pharmacies
10.5.1. Canada Pharmaceutical Market, By Hospital Pharmacies, 2017-2030 (US$ Mn)
10.5.2. Market Dynamics for Hospital Pharmacies
10.5.2.1. Drivers
10.5.2.2. Restraints
10.5.2.3. Opportunities
10.5.2.4. Trends
10.6. Online Pharmacies
10.6.1. Canada Pharmaceutical Market, By Online Pharmacies, 2017-2030 (US$ Mn)
10.6.2. Market Dynamics for Online Pharmacies
10.6.2.1. Drivers
10.6.2.2. Restraints
10.6.2.3. Opportunities
10.6.2.4. Trends
11. Canada Pharmaceutical Market, By Regulatory Compliance and Approval
11.1. Canada Pharmaceutical Market Overview, by Regulatory Compliance and Approval
11.1.1. Canada Pharmaceutical Market Revenue Share, By Regulatory Compliance and Approval, 2022 Vs 2030 (in %)
11.2. Health Canada
11.2.1. Canada Pharmaceutical Market, By Health Canada, 2017-2030 (US$ Mn)
11.2.2. Market Dynamics for Health Canada
11.2.2.1. Drivers
11.2.2.2. Restraints
11.2.2.3. Opportunities
11.2.2.4. Trends
11.3. Patent and Generic Drugs
11.3.1. Canada Pharmaceutical Market, By Patent and Generic Drugs, 2017-2030 (US$ Mn)
11.3.2. Market Dynamics for Patent and Generic Drugs
11.3.2.1. Drivers
11.3.2.2. Restraints
11.3.2.3. Opportunities
11.3.2.4. Trends
11.4. Biosimilars
11.4.1. Canada Pharmaceutical Market, By Biosimilars, 2017-2030 (US$ Mn)
11.4.2. Market Dynamics for Biosimilars
11.4.2.1. Drivers
11.4.2.2. Restraints
11.4.2.3. Opportunities
11.4.2.4. Trends
11.5. Clinical Trials
11.5.1. Canada Pharmaceutical Market, By Clinical Trials, 2017-2030 (US$ Mn)
11.5.2. Market Dynamics for Clinical Trials
11.5.2.1. Drivers
11.5.2.2. Restraints
11.5.2.3. Opportunities
11.5.2.4. Trends
12. Canada Pharmaceutical Market, By Research and Development (R&D)
12.1. Canada Pharmaceutical Market Overview, by Research and Development (R&D)
12.1.1. Canada Pharmaceutical Market Revenue Share, By Research and Development (R&D), 2022 Vs 2030 (in %)
12.2. Innovative Drug Discovery
12.2.1. Canada Pharmaceutical Market, By Innovative Drug Discovery, 2017-2030 (US$ Mn)
12.2.2. Market Dynamics for Innovative Drug Discovery
12.2.2.1. Drivers
12.2.2.2. Restraints
12.2.2.3. Opportunities
12.2.2.4. Trends
12.3. Clinical Development
12.3.1. Canada Pharmaceutical Market, By Clinical Development, 2017-2030 (US$ Mn)
12.3.2. Market Dynamics for Clinical Development
12.3.2.1. Drivers
12.3.2.2. Restraints
12.3.2.3. Opportunities
12.3.2.4. Trends
12.4. Regulatory Affairs and Approvals
12.4.1. Canada Pharmaceutical Market, By Regulatory Affairs and Approvals, 2017-2030 (US$ Mn)
12.4.2. Market Dynamics for Regulatory Affairs and Approvals
12.4.2.1. Drivers
12.4.2.2. Restraints
12.4.2.3. Opportunities
12.4.2.4. Trends
13. Canada Pharmaceutical Market, By Pharmaceutical Services and Solutions
13.1. Canada Pharmaceutical Market Overview, by Pharmaceutical Services and Solutions
13.1.1. Canada Pharmaceutical Market Revenue Share, By Pharmaceutical Services and Solutions, 2022 Vs 2030 (in %)
13.2. Pharmaceutical Services Providers
13.2.1. Canada Pharmaceutical Market, By Pharmaceutical Services Providers, 2017-2030 (US$ Mn)
13.2.2. Market Dynamics for Pharmaceutical Services Providers
13.2.2.1. Drivers
13.2.2.2. Restraints
13.2.2.3. Opportunities
13.2.2.4. Trends
13.3. Pharmaceutical Packaging Solutions
13.3.1. Canada Pharmaceutical Market, By Pharmaceutical Packaging Solutions, 2017-2030 (US$ Mn)
13.3.2. Market Dynamics for Pharmaceutical Packaging Solutions
13.3.2.1. Drivers
13.3.2.2. Restraints
13.3.2.3. Opportunities
13.3.2.4. Trends
13.4. Pharmaceutical Consulting and Contract Research
13.4.1. Canada Pharmaceutical Market, By Pharmaceutical Consulting and Contract Research, 2017-2030 (US$ Mn)
13.4.2. Market Dynamics for Pharmaceutical Consulting and Contract Research
13.4.2.1. Drivers
13.4.2.2. Restraints
13.4.2.3. Opportunities
13.4.2.4. Trends
14. Canada Pharmaceutical Market, By Pharmaceutical Manufacturing
14.1. Canada Pharmaceutical Market Overview, by Pharmaceutical Manufacturing
14.1.1. Canada Pharmaceutical Market Revenue Share, By Pharmaceutical Manufacturing, 2022 Vs 2030 (in %)
14.2. Domestic Manufacturing
14.2.1. Canada Pharmaceutical Market, By Domestic Manufacturing, 2017-2030 (US$ Mn)
14.2.2. Market Dynamics for Domestic Manufacturing
14.2.2.1. Drivers
14.2.2.2. Restraints
14.2.2.3. Opportunities
14.2.2.4. Trends
14.3. Imported Pharmaceuticals
14.3.1. Canada Pharmaceutical Market, By Imported Pharmaceuticals, 2017-2030 (US$ Mn)
14.3.2. Market Dynamics for Imported Pharmaceuticals
14.3.2.1. Drivers
14.3.2.2. Restraints
14.3.2.3. Opportunities
14.3.2.4. Trends
15. Company Profiles
15.1. Johnson & Johnson
15.1.1. Company Overview
15.1.2. Products/Services Portfolio
15.1.3. Geographical Presence
15.1.4. SWOT Analysis
15.1.5. Financial Summary
15.1.5.1. Market Revenue and Net Profit (2019-2022)
15.1.5.2. Business Segment Revenue Analysis
15.1.5.3. Geographical Revenue Analysis
15.2. Novartis International AG
15.3. Abbott Laboratories
15.4. Merck & Co. Inc.
15.5. Pfizer Inc.
15.6. F. Hoffmann-La Roche AG
15.7. Bristol Myers Squibb Company
15.8. Eli Lilly and Company
15.9. AbbVie Inc.
15.10. Apotex Inc.
15.11. Others
16. Research Methodology
16.1. Research Methodology
16.2. Phase I – Secondary Research
16.3. Phase II – Data Modelling
16.3.1. Company Share Analysis Model
16.3.2. Revenue Based Modelling
16.4. Phase III – Primary Research
16.5. Research Limitations
16.5.1. Assumptions

List of Figures
FIG. 1 Canada Pharmaceutical Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Canada Pharmaceutical Market Segmentation
FIG. 4 Canada Pharmaceutical Market, by Pharmaceutical Product Categories, 2022 (US$ Mn)
FIG. 5 Canada Pharmaceutical Market, by Therapeutic Areas, 2022 (US$ Mn)
FIG. 6 Canada Pharmaceutical Market, by Pharmaceutical Distribution Channels, 2022 (US$ Mn)
FIG. 7 Canada Pharmaceutical Market, by Regulatory Compliance and Approval, 2022 (US$ Mn)
FIG. 8 Canada Pharmaceutical Market, by Research and Development (R&D), 2022 (US$ Mn)
FIG. 9 Canada Pharmaceutical Market, by Pharmaceutical Services and Solutions, 2022 (US$ Mn)
FIG. 10 Canada Pharmaceutical Market, by Pharmaceutical Manufacturing, 2022 (US$ Mn)
FIG. 11 Attractive Investment Proposition, by Pharmaceutical Product Categories, 2022
FIG. 12 Attractive Investment Proposition, by Therapeutic Areas, 2022
FIG. 13 Attractive Investment Proposition, by Pharmaceutical Distribution Channels, 2022
FIG. 14 Attractive Investment Proposition, by Regulatory Compliance and Approval, 2022
FIG. 15 Attractive Investment Proposition, by Research and Development (R&D), 2022
FIG. 16 Attractive Investment Proposition, by Pharmaceutical Services and Solutions, 2022
FIG. 17 Attractive Investment Proposition, by Pharmaceutical Manufacturing, 2022
FIG. 18 Canada Market Share Analysis of Key Pharmaceutical Market Manufacturers, 2022
FIG. 19 Canada Market Positioning of Key Pharmaceutical Market Manufacturers, 2022
FIG. 20 Canada Pharmaceutical Market Value Contribution, By Pharmaceutical Product Categories, 2022 & 2030 (Value %)
FIG. 21 Canada Pharmaceutical Market, by Prescription Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 22 Canada Pharmaceutical Market, by Over-the-Counter (OTC) Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 23 Canada Pharmaceutical Market, by Generic Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 24 Canada Pharmaceutical Market, by Biopharmaceuticals and Biologics, Value, 2017-2030 (US$ Mn)
FIG. 25 Canada Pharmaceutical Market, by Specialty Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 26 Canada Pharmaceutical Market, by Vaccines, Value, 2017-2030 (US$ Mn)
FIG. 27 Canada Pharmaceutical Market Value Contribution, By Therapeutic Areas, 2022 & 2030 (Value %)
FIG. 28 Canada Pharmaceutical Market, by Cardiovascular Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 29 Canada Pharmaceutical Market, by Oncology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 30 Canada Pharmaceutical Market, by Central Nervous System (CNS) Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 31 Canada Pharmaceutical Market, by Infectious Disease Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 32 Canada Pharmaceutical Market, by Respiratory Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 33 Canada Pharmaceutical Market, by Gastrointestinal Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 34 Canada Pharmaceutical Market, by Immunology and Rheumatology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 35 Canada Pharmaceutical Market, by Endocrinology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 36 Canada Pharmaceutical Market, by Dermatology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 37 Canada Pharmaceutical Market, by Ophthalmology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 38 Canada Pharmaceutical Market, by Hematology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 39 Canada Pharmaceutical Market, by Urology Pharmaceuticals, Value, 2017-2030 (US$ Mn)
FIG. 40 Canada Pharmaceutical Market Value Contribution, By Pharmaceutical Distribution Channels, 2022 & 2030 (Value %)
FIG. 41 Canada Pharmaceutical Market, by Pharmaceutical Manufacturers, Value, 2017-2030 (US$ Mn)
FIG. 42 Canada Pharmaceutical Market, by Pharmaceutical Wholesalers and Distributors, Value, 2017-2030 (US$ Mn)
FIG. 43 Canada Pharmaceutical Market, by Community Pharmacies, Value, 2017-2030 (US$ Mn)
FIG. 44 Canada Pharmaceutical Market, by Hospital Pharmacies, Value, 2017-2030 (US$ Mn)
FIG. 45 Canada Pharmaceutical Market, by Online Pharmacies, Value, 2017-2030 (US$ Mn)
FIG. 46 Canada Pharmaceutical Market Value Contribution, By Regulatory Compliance and Approval, 2022 & 2030 (Value %)
FIG. 47 Canada Pharmaceutical Market, by Health Canada, Value, 2017-2030 (US$ Mn)
FIG. 48 Canada Pharmaceutical Market, by Patent and Generic Drugs, Value, 2017-2030 (US$ Mn)
FIG. 49 Canada Pharmaceutical Market, by Biosimilars, Value, 2017-2030 (US$ Mn)
FIG. 50 Canada Pharmaceutical Market, by Clinical Trials, Value, 2017-2030 (US$ Mn)
FIG. 51 Canada Pharmaceutical Market Value Contribution, By Research and Development (R&D), 2022 & 2030 (Value %)
FIG. 52 Canada Pharmaceutical Market, by Innovative Drug Discovery, Value, 2017-2030 (US$ Mn)
FIG. 53 Canada Pharmaceutical Market, by Clinical Development, Value, 2017-2030 (US$ Mn)
FIG. 54 Canada Pharmaceutical Market, by Regulatory Affairs and Approvals, Value, 2017-2030 (US$ Mn)
FIG. 55 Canada Pharmaceutical Market Value Contribution, By Pharmaceutical Services and Solutions, 2022 & 2030 (Value %)
FIG. 56 Canada Pharmaceutical Market, by Pharmaceutical Services Providers, Value, 2017-2030 (US$ Mn)
FIG. 57 Canada Pharmaceutical Market, by Pharmaceutical Packaging Solutions, Value, 2017-2030 (US$ Mn)
FIG. 58 Canada Pharmaceutical Market, by Pharmaceutical Consulting and Contract Research, Value, 2017-2030 (US$ Mn)
FIG. 59 Canada Pharmaceutical Market Value Contribution, By Pharmaceutical Manufacturing, 2022 & 2030 (Value %)
FIG. 60 Canada Pharmaceutical Market, by Domestic Manufacturing, Value, 2017-2030 (US$ Mn)
FIG. 61 Canada Pharmaceutical Market, by Imported Pharmaceuticals, Value, 2017-2030 (US$ Mn)

List of Tables
TABLE 1 Market Snapshot: Canada Pharmaceutical Market
TABLE 2 Canada Pharmaceutical Market: Market Drivers Impact Analysis
TABLE 3 Canada Pharmaceutical Market: Market Restraints Impact Analysis
TABLE 4 Canada Pharmaceutical Market, by Competitive Benchmarking, 2022
TABLE 5 Canada Pharmaceutical Market, by Geographical Presence Analysis, 2022
TABLE 6 Canada Pharmaceutical Market, by Key Strategies Analysis, 2022
TABLE 7 Canada Pharmaceutical Market, by Prescription Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 8 Canada Pharmaceutical Market, by Prescription Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 9 Canada Pharmaceutical Market, by Over-the-Counter (OTC) Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 10 Canada Pharmaceutical Market, by Over-the-Counter (OTC) Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 11 Canada Pharmaceutical Market, by Generic Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 12 Canada Pharmaceutical Market, by Generic Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 13 Canada Pharmaceutical Market, by Biopharmaceuticals and Biologics, 2017-2022 (US$ Mn)
TABLE 14 Canada Pharmaceutical Market, by Biopharmaceuticals and Biologics, 2023-2030 (US$ Mn)
TABLE 15 Canada Pharmaceutical Market, by Specialty Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 16 Canada Pharmaceutical Market, by Specialty Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 17 Canada Pharmaceutical Market, by Vaccines, 2017-2022 (US$ Mn)
TABLE 18 Canada Pharmaceutical Market, by Vaccines, 2023-2030 (US$ Mn)
TABLE 19 Canada Pharmaceutical Market, by Cardiovascular Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 20 Canada Pharmaceutical Market, by Cardiovascular Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 21 Canada Pharmaceutical Market, by Oncology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 22 Canada Pharmaceutical Market, by Oncology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 23 Canada Pharmaceutical Market, by Central Nervous System (CNS) Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 24 Canada Pharmaceutical Market, by Central Nervous System (CNS) Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 25 Canada Pharmaceutical Market, by Infectious Disease Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 26 Canada Pharmaceutical Market, by Infectious Disease Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 27 Canada Pharmaceutical Market, by Respiratory Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 28 Canada Pharmaceutical Market, by Respiratory Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 29 Canada Pharmaceutical Market, by Gastrointestinal Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 30 Canada Pharmaceutical Market, by Gastrointestinal Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 31 Canada Pharmaceutical Market, by Immunology and Rheumatology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 32 Canada Pharmaceutical Market, by Immunology and Rheumatology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 33 Canada Pharmaceutical Market, by Endocrinology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 34 Canada Pharmaceutical Market, by Endocrinology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 35 Canada Pharmaceutical Market, by Dermatology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 36 Canada Pharmaceutical Market, by Dermatology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 37 Canada Pharmaceutical Market, by Ophthalmology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 38 Canada Pharmaceutical Market, by Ophthalmology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 39 Canada Pharmaceutical Market, by Hematology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 40 Canada Pharmaceutical Market, by Hematology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 41 Canada Pharmaceutical Market, by Urology Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 42 Canada Pharmaceutical Market, by Urology Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 43 Canada Pharmaceutical Market, by Pharmaceutical Manufacturers, 2017-2022 (US$ Mn)
TABLE 44 Canada Pharmaceutical Market, by Pharmaceutical Manufacturers, 2023-2030 (US$ Mn)
TABLE 45 Canada Pharmaceutical Market, by Pharmaceutical Wholesalers and Distributors, 2017-2022 (US$ Mn)
TABLE 46 Canada Pharmaceutical Market, by Pharmaceutical Wholesalers and Distributors, 2023-2030 (US$ Mn)
TABLE 47 Canada Pharmaceutical Market, by Community Pharmacies, 2017-2022 (US$ Mn)
TABLE 48 Canada Pharmaceutical Market, by Community Pharmacies, 2023-2030 (US$ Mn)
TABLE 49 Canada Pharmaceutical Market, by Hospital Pharmacies, 2017-2022 (US$ Mn)
TABLE 50 Canada Pharmaceutical Market, by Hospital Pharmacies, 2023-2030 (US$ Mn)
TABLE 51 Canada Pharmaceutical Market, by Online Pharmacies, 2017-2022 (US$ Mn)
TABLE 52 Canada Pharmaceutical Market, by Online Pharmacies, 2023-2030 (US$ Mn)
TABLE 53 Canada Pharmaceutical Market, by Health Canada, 2017-2022 (US$ Mn)
TABLE 54 Canada Pharmaceutical Market, by Health Canada, 2023-2030 (US$ Mn)
TABLE 55 Canada Pharmaceutical Market, by Patent and Generic Drugs, 2017-2022 (US$ Mn)
TABLE 56 Canada Pharmaceutical Market, by Patent and Generic Drugs, 2023-2030 (US$ Mn)
TABLE 57 Canada Pharmaceutical Market, by Biosimilars, 2017-2022 (US$ Mn)
TABLE 58 Canada Pharmaceutical Market, by Biosimilars, 2023-2030 (US$ Mn)
TABLE 59 Canada Pharmaceutical Market, by Clinical Trials, 2017-2022 (US$ Mn)
TABLE 60 Canada Pharmaceutical Market, by Clinical Trials, 2023-2030 (US$ Mn)
TABLE 61 Canada Pharmaceutical Market, by Innovative Drug Discovery, 2017-2022 (US$ Mn)
TABLE 62 Canada Pharmaceutical Market, by Innovative Drug Discovery, 2023-2030 (US$ Mn)
TABLE 63 Canada Pharmaceutical Market, by Clinical Development, 2017-2022 (US$ Mn)
TABLE 64 Canada Pharmaceutical Market, by Clinical Development, 2023-2030 (US$ Mn)
TABLE 65 Canada Pharmaceutical Market, by Regulatory Affairs and Approvals, 2017-2022 (US$ Mn)
TABLE 66 Canada Pharmaceutical Market, by Regulatory Affairs and Approvals, 2023-2030 (US$ Mn)
TABLE 67 Canada Pharmaceutical Market, by Pharmaceutical Services Providers, 2017-2022 (US$ Mn)
TABLE 68 Canada Pharmaceutical Market, by Pharmaceutical Services Providers, 2023-2030 (US$ Mn)
TABLE 69 Canada Pharmaceutical Market, by Pharmaceutical Packaging Solutions, 2017-2022 (US$ Mn)
TABLE 70 Canada Pharmaceutical Market, by Pharmaceutical Packaging Solutions, 2023-2030 (US$ Mn)
TABLE 71 Canada Pharmaceutical Market, by Pharmaceutical Consulting and Contract Research, 2017-2022 (US$ Mn)
TABLE 72 Canada Pharmaceutical Market, by Pharmaceutical Consulting and Contract Research, 2023-2030 (US$ Mn)
TABLE 73 Canada Pharmaceutical Market, by Domestic Manufacturing, 2017-2022 (US$ Mn)
TABLE 74 Canada Pharmaceutical Market, by Domestic Manufacturing, 2023-2030 (US$ Mn)
TABLE 75 Canada Pharmaceutical Market, by Imported Pharmaceuticals, 2017-2022 (US$ Mn)
TABLE 76 Canada Pharmaceutical Market, by Imported Pharmaceuticals, 2023-2030 (US$ Mn)
TABLE 77 Canada Pharmaceutical Market, by Pharmaceutical Product Categories, 2017-2022 (US$ Mn)
TABLE 78 Canada Pharmaceutical Market, by Pharmaceutical Product Categories, 2023-2030 (US$ Mn)
TABLE 79 Canada Pharmaceutical Market, by Therapeutic Areas, 2017-2022 (US$ Mn)
TABLE 80 Canada Pharmaceutical Market, by Therapeutic Areas, 2023-2030 (US$ Mn)
TABLE 81 Canada Pharmaceutical Market, by Pharmaceutical Distribution Channels, 2017-2022 (US$ Mn)
TABLE 82 Canada Pharmaceutical Market, by Pharmaceutical Distribution Channels, 2023-2030 (US$ Mn)
TABLE 83 Canada Pharmaceutical Market, by Regulatory Compliance and Approval, 2017-2022 (US$ Mn)
TABLE 84 Canada Pharmaceutical Market, by Regulatory Compliance and Approval, 2023-2030 (US$ Mn)
TABLE 85 Canada Pharmaceutical Market, by Research and Development (R&D), 2017-2022 (US$ Mn)
TABLE 86 Canada Pharmaceutical Market, by Research and Development (R&D), 2023-2030 (US$ Mn)
TABLE 87 Canada Pharmaceutical Market, by Pharmaceutical Services and Solutions, 2017-2022 (US$ Mn)
TABLE 88 Canada Pharmaceutical Market, by Pharmaceutical Services and Solutions, 2023-2030 (US$ Mn)
TABLE 89 Canada Pharmaceutical Market, by Pharmaceutical Manufacturing, 2017-2022 (US$ Mn)
TABLE 90 Canada Pharmaceutical Market, by Pharmaceutical Manufacturing, 2023-2030 (US$ Mn)

How big is the Canadian pharmaceuticals market right now?

In 2022, the market for Canadian pharmaceuticals was estimated to be worth USD 31154.5 million.

What is the Canadian pharmaceutical market’s anticipated growth rate from 2023 to 2030?

The market for Canadian pharmaceuticals is anticipated to increase at a CAGR of 5.20% from 2023 to 2030, reaching USD 46735.47 million in 2030.

Which market category is in the lead for the pharmaceutical product categories?

Over-the-counter (OTC) pharmaceuticals are the most popular pharmaceutical product categories.

Which segment is leading the market in terms of therapeutic areas?

The notable segment is cardiovascular pharmaceuticals by therapeutic areas.

Which pharmaceutical distribution channels segment is estimated to have the highest CAGR throughout the forecast period?

Which pharmaceutical distribution channels segment is estimated to have the highest CAGR throughout the forecast period?

Qatar Dental Care Market

Published:
Report ID: 30608

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Hepatic Encephalopathy Market

Published:
Report ID: 33664

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Guidewires Market

Published:
Report ID: 6790

3D Printing for Personalized Healthcare Market

Published:
Report ID: 33603

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

In Vitro Diagnostic (IVD) Kit Market

Published:
Report ID: 33580

North America Medical Headgears Market

Published:
Report ID: 33554

Purchase Options

$999
Delivery Format: Excel.
$1999
Designed for the individual purchaser.
$2999
Users located at a single corporate site or regional office.
$3999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN